The authors observed that anti-PD-1 therapy (nivolumab), agents that target immune regulatory checkpoints, inhibited tumor growth in MSI-H CRC, correlating with an increase of human T cells, in particular CD8 T cells and INF-γ-producing CD8+ tumor-infiltrating leukocytes (TILs). Here, PDCD1 is linked to neoplasm.